Menu
Innovation Observatory > Reports > Haematology and Blood Products

Results

Drugs

Drugs

December 2017

Voxelotor for Sickle Cell Disease

Voxelotor is as an oral, once-daily therapy that is being developed for treatment of SCD. It is designed to work by helping haemoglobin hold onto more oxygen as the red blood cells travel through the body.

Drugs

December 2017

Crizanlizumab (formerly SelG1) for Sickle Cell Disease

Crizanlizumab is a medicine under development for the preventative treatment of SCD painful crisis.

Drugs

August 2017

Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are a group of blood disorders, in which the bone marrow does not produce enough healthy red blood cells, white blood cells and/or platelets. Faulty cells often die earlier than normal cells and the body destroys some abnormal cells, leaving the patient with low blood counts. This can result in anaemia (not …

Drugs

February 2017

Eltrombopag (Revolade) for severe aplastic anaemia – first line

Eltrombopag (Revolade) is a new drug to treat severe aplastic anaemia. Eltrombopag is taken by mouth and makes the body produce more platelet cells by activating a hormone called thrombopoietin.

Drugs

February 2017

Cinryze (C1 inhibitor) for treatment and prevention of recurrent attacks of hereditary angioedema in children

Hereditary angioedema (HAE) is a rare inherited condition that causes swelling of the tissues (angioedema). These swellings happen suddenly and can affect any part of the body, including the hands and feet, arms and legs, trunk, intestines, genital organs, face, tongue, neck and airway. Cinryze is a drug that is already used to treat adolescents …

Drugs

August 2016

Momelotinib for myelofibrosis

Myelofibrosis is a rare condition affecting the bone marrow and most people with this condition do not have any symptoms. Bone marrow is where blood cells are made. In myelofibrosis, scar tissue builds up inside the bone marrow and blood cells are not made properly. Occasionally the spleen (which functions as a blood filter) may …

Drugs

July 2016

Caplacizumab for thrombotic thrombocytopenic purpura

Caplacizumab is a drug that is being given for the treatment of thrombotic thrombocytopenic purpura. The drug is injected under the skin and given alongside the current treatment of plasma exchange.

Drugs

July 2016

Begelomab (Begesand) for steroid resistant acute graft versus host disease

Begelomab is a new drug for people whose first treatment for GvHD has failed. Begelomab is given in a drip (directly into a vein). Begelomab is currently being studied to see how well it works and whether they it is safe to use in people with GvHD. If begelomab is licensed for use in the …

Drugs

June 2016

Vepoloxamer for vaso-occlusive crises in sickle cell disease – first line

Sickle cell disease is an inherited disease that causes red blood cells to develop abnormally. Normal red blood cells are flexible and disc shaped. In sickle cell disease, the cells become rigid and sickle shaped. This causes blockages in blood vessels leading to extreme pain; this is called a vaso-occlusive crisis. Vepoloxamer is a new …

Get Alerts